We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




PCR Market Rises to USD3.5 Billion for 2015

By LabMedica International staff writers
Posted on 04 Jul 2016
The total PCR (polymerase chain reaction) technologies market was valued at about USD3.5 billion for 2015, up from USD3.2 billion in 2013, according to Kalorama Information (New York, NY, USA), a healthcare market research company.

PCR is a biochemical technology in molecular biology that is used to amplify a single copy or a few copies of a piece of DNA across several orders of magnitude, generating thousands to millions of copies of a particular DNA sequence. More...
PCR technologies are being increasingly used for medical testing, particularly for diagnosing bacterial and infectious diseases, detecting antibiotic resistance, and for cancer exploration of mutations and detection of genetic abnormalities. These technologies, particularly quantitative PCR (qPCR) and digital PCR (dPCR), hold great promise for expanding diagnostic applications.

qPCR is mainly used for DNA sequencing and gene expression in stem cell research, oncology and genetic disease research, pathogen detection and infectious disease research, and plant sciences research. It is also utilized in forensic science, food and safety applications, genetically modified organisms (GMO) testing, and detection of genetic abnormalities and cancer mutations. The coming years are expected to witness an expansion in qPCR-based diagnostic tests.

On the other hand, dPCR provides absolute measurement of copies and is the next logical step in PCR evolution. dPCR partitions sample and reaction components into hundreds or thousands of reaction chambers to count the presence or absence of molecules. The technology provides greatly improved sensitivity in the detection of rare mutations and sequences, and is likely to become increasingly important with the evolution of clinical applications.

“qPCR has established itself as the workhorse in the research laboratory,” said Bruce Carlson, Publisher of Kalorama Information. “But dPCR’s potential is greater in diagnostic applications due to its sensitivity, precision, robustness, and reproducibility.”

The US and European PCR technology markets have been witnessing intensifying competition, resulting in increasing participation in other regions like Asia and Latin America. Among the number of companies in the PCR technology market are large multi-product companies like Thermo Fisher Scientific (Waltham, MA, USA), Roche Holding AG (Basel, Switzerland), and Abbott (Abbot Park, IL, USA), as well as small niche developers such as RainDance Technologies (Billerica, MA, USA).

Related Links:
Kalorama Information
Thermo Fisher Scientific
Roche
Abbott
RainDance Technologies

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Connectivity Solution
EKF Link
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Mayo Clinic researchers used genetic data from nearly 50,000 participants to identify sickle cell and beta-thalassemia carrier traits, highlighting how population-scale testing can complement existing screening (Image Credit: Adobe Stock)

Genetic Testing Offers Opportunities for Earlier Blood Disorder Carrier Identification

Inherited hemoglobin disorders can affect oxygen transport, yet individuals who carry only a trait may remain unaware of their status. People with sickle cell trait or beta-thalassemia trait often have... Read more

Microbiology

view channel
Image Credit: Adobe Stock

Decentralized Laboratory Network Improves Detection of Viral Hemorrhagic Fevers in Guinea

Viral hemorrhagic fevers remain a major diagnostic challenge in West Africa because their early symptoms can resemble those of other febrile illnesses. The 2014–2016 Ebola epidemic underscored the need... Read more

Pathology

view channel
Image Credit: Adobe Stock

AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification

In early-stage breast cancer, precision oncology relies on biological information to guide personalized treatment decisions. Because access to tissue-based genomic testing may be limited, there is growing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.